Kidney Cancer

RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery

By

Jody A. Charnow, Editor

Publish Date October 9, 2019

Following nephrectomy for renal cell carcinoma with lymph node involvement, patients have a 5-year survival rate of only 28%, a new study found.

CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC

By

Leah Lawrence

Publish Date September 5, 2019

Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.

Looking at Survival Differently in Patients With Metastatic Kidney Cancer

By

Christina Bennett, MS

Publish Date September 3, 2019

Conditional survival may more accurately assess prognosis than traditional survival for patients with metastatic kidney cancer, but the metric is not without its caveats.

Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?

By

Susan Moench, PhD, PA-C

Publish Date August 30, 2019

A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.

Cryoablation vs PN for pT1b RCC Predicts Greater Cancer Death Risk

By

Jody A. Charnow, Editor

Publish Date August 6, 2019

Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.